本文選題：芪附溫陽湯 + 擴張型心肌病�。� 參考：《山東中醫(yī)藥大學》2016年碩士論文

【摘要】：目的:本課題旨在探索芪附溫陽湯配合常規(guī)西藥治療擴張型心肌病與單純常規(guī)西藥治療相比較臨床療效有無差異,評價芪附溫陽湯治療擴張型心肌病的臨床療效并探索其作用機理,為其指導擴張型心肌病的診療提供一定的臨床依據(jù)。方法:選取50例擴張型心肌病心腎陽虛證型患者,隨機分為對照組和治療組。對照組采取西藥常規(guī)治療,治療組在西藥常規(guī)治療基礎上配合芪附溫陽湯。以8周為1個療程,記錄患者治療前后的中醫(yī)癥候積分、心功能分級(NYHA分級法)、血清N末端腦鈉尿肽原(NT-proBNP)、左心室舒張末期內徑(LVEDD)、左心室射血分數(shù)(LVEF)、明尼蘇達心力衰竭患者生活質量評分,并應用“SPSS17.0”統(tǒng)計軟件對其進行統(tǒng)計學分析。結果:(1)治療組心功能分級療效總有效率為88%,對照組總有效率60%,采用秩和檢驗對兩組有效率進行比較,治療組療效優(yōu)于對照組(P0.05)。(2)治療后兩組患者中醫(yī)癥候積分、NT-proBNP、LVEF、明尼蘇達心力衰竭患者生活質量評分與治療前比較均有顯著性差異(P0.01),對兩組進行組間比較,治療組優(yōu)于對照組(P0.05)。(3)治療后兩組患者LVEDD與治療前比較有顯著性差異(P0.01),對兩組進行組間比較,治療組與對照組無統(tǒng)計學差異(P0.05)。(4)兩組患者治療前后安全性指標均無明顯異常變化(P0.05)。結論:芪附溫陽湯對擴張型心肌病心腎陽虛型患者的中醫(yī)癥候積分、心功能分級、NT-proBNP、左心室射血分數(shù)、明尼蘇達心力衰竭患者生活質量評分均具有明顯改善作用;對肝腎功能無明顯影響,安全性良好。
[Abstract]:Objective: to explore the clinical effect of Qifu Wenyang decoction combined with conventional western medicine in the treatment of dilated cardiomyopathy. To evaluate the clinical effect of Qifuwenyang decoction in the treatment of dilated cardiomyopathy and to explore its mechanism, and to provide some clinical basis for guiding the diagnosis and treatment of dilated cardiomyopathy. Methods: 50 cases of dilated cardiomyopathy with deficiency of heart and kidney yang were randomly divided into control group and treatment group. The control group was treated with routine western medicine, and the treatment group was treated with Qifu Wenyang decoction on the basis of routine western medicine treatment. Taking 8 weeks as a course of treatment, the scores of TCM symptoms before and after treatment were recorded. NYHA classification of cardiac function, NT-proBNPN, LVEDDD, LVEFN, LVEFV, and quality of life of patients with heart failure in Minnesota were analyzed with SPSS 17.0 statistical software. Results the total effective rate of heart function grading in the treatment group was 88 and that in the control group was 60. The effective rate of the two groups was compared by rank sum test. The curative effect of the treatment group was better than that of the control group (P 0.05, P 0.05, P < 0.05). After the treatment, the score of TCM symptom and the score of quality of life of the patients with Minnesota heart failure were significantly higher than those of the control group (P 0.01), and the difference between the two groups was also significant (P 0.01), and there were significant differences between the two groups in the score of quality of life of the patients with heart failure in Minnesota. There was significant difference in LVEDD between the two groups after treatment and before treatment. There was no significant difference between the treatment group and the control group in the safety indexes of the two groups before and after treatment. Conclusion: Qifuwenyang decoction can significantly improve the scores of TCM symptoms, cardiac function grading and NT-proBNPs, left ventricular ejection fraction (LVEF), and Minnesota heart failure patients' quality of life (QOL) in patients with heart and kidney yang deficiency of dilated cardiomyopathy. It has no obvious effect on liver and kidney function and is safe.
【學位授予單位】：山東中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R259

【參考文獻】

相關期刊論文 前10條

1 蔣瑞俠;;二丁酰環(huán)磷腺苷鈣治療擴張型心肌病心力衰竭的療效觀察[J];河南醫(yī)學研究;2015年08期

2 洪卓周;林宇鵬;;丙種球蛋白治療擴張型心肌病的療效觀察[J];中國醫(yī)藥科學;2015年15期

3 胡茜茹;程自平;趙韌;;心臟再同步化治療對擴張型心肌病患者左心房功能的影響[J];安徽醫(yī)藥;2015年06期

4 呂洋;陳巖;楊積武;;強心寧煎劑治療擴張型心肌病臨床觀察[J];遼寧中醫(yī)藥大學學報;2015年06期

5 巫雪飛;黃燕;房曉楠;鄒長虹;周瓊;張宇輝;呂蓉;張健;;擴張型心肌病患者經(jīng)標準藥物治療后左心室射血分數(shù)恢復正常的發(fā)生率及預測因素分析[J];中國循環(huán)雜志;2015年05期

6 張敏;王仁平;王雷;任曉倩;王淑敏;黃瑞霞;王軍茂;王寧寧;閆杰亮;;補元養(yǎng)心湯對擴張型心肌病心腎功能不全的臨床療效研究[J];河北中醫(yī)藥學報;2015年01期

7 鄭彬彬;;觀察小劑量甲狀腺素治療擴張型心肌病心衰的療效[J];中西醫(yī)結合心血管病電子雜志;2015年08期

8 楊柳;唐其柱;郭毅;;骨髓干細胞移植治療擴張性心肌病療效及安全性的系統(tǒng)評價[J];中國循證醫(yī)學雜志;2015年02期

9 金靜;朱宗成;盛曉東;周建龍;范韜;金驍琦;;CRT和藥物治療對擴張型心肌病患者心功能影響的臨床對比研究[J];齊齊哈爾醫(yī)學院學報;2015年02期

10 李玉芳;;擴張型心肌病中醫(yī)理論探微[J];陜西中醫(yī);2014年12期

，

本文編號：2017310